Challenges and opportunities in dermal/transdermal delivery

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

Bibliography

• 1  Jain PharmaBiotech report. Transdermal drug delivery-technologies, markets and companies (2005).
  Google Scholar
• 2  Prausnitz MR, Langer R. Transdermal drug delivery. Nat. Biotech.26(11),1261–1268 (2008).
  Medline CASGoogle Scholar
• 3  Martin E (Ed.). Remington’s Practice of Pharmacy. Mack Publishing Co, Easton, PA, USA (2003).
  Google Scholar
• 4  Scheindlin S. Transdermal drug delivery: past, present, future. Mol. Interv.4(6),308–312 (2004).
  MedlineGoogle Scholar
• 5  Cevc G, Vierl U. Nanotechnology and the transdermal route. A state of the art review and critical appraisal. J. Control. Release141(11),277–299 (2010).
  Medline CASGoogle Scholar
• 6  Tiwary AK, Sapra B, Jain S. Innovations in transdermal drug delivery: formulations and techniques. Recent Pat. Drug Deliv. Formul.1,23–36 (2007).
  Medline CASGoogle Scholar
• 7  Samad A, Ullah Z, Alam MI, Wais M, Shams MS. Transdermal drug delivery system: patent reviews. Recent Pat. Drug Deliv. Formul.3(2),143–52 (2009).
  Medline CASGoogle Scholar
• 8  Rizwan M, Aqil M, Talegaonkar S, Azeem A, Sultana Y, Ali A. Enhanced transdermal drug delivery techniques: an extensive review of patents. Recent Pat. Drug Deliv. Formul.3(2),105–124 (2009).
  Medline CASGoogle Scholar
• 9  Prausnitz MR, Mitragotri S, Langer R. Current status and future potential of transdermal drug delivery. Nat. Rev. Drug Discov.3(2),115–124 (2004).
  Medline CASGoogle Scholar
• 10  Banga AK. Microporation applications for enhancing drug delivery. Expert Opin. Drug Deliv.6(4),343–54 (2009).
  Medline CASGoogle Scholar
• 11  Kalluri H, Banga AK. Microneedles and transdermal drug delivery. J. Drug Del. Sci. Tech.19(5),303–310 (2009).
  CASGoogle Scholar
• 12  Bos JD, Meinardi MMHM. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp. Dermatol.9(3),165–169 (2000).
  Medline CASGoogle Scholar
• 13  Thong HY, Zhai H, Maibach HI. Percutaneous penetration enhancers: an overview. Skin Pharmacol. Physiol.20(6) 272–282 (2007).▪ Recent review containing extensive list of popular chemical permeation enhancers.
  MedlineGoogle Scholar
• 14  Michaels AS, Chandrasekaran SK, Shaw JE. Drug permeation through human skin. Theory and in vitro experimental measurement. AIChE J.21(5),985–996 (1975).
  CASGoogle Scholar
• 15  Albery WJ, Hadgraft J. Percutaneous absorption: in vivo experiments. J. Pharm. Pharmacol.31(3),140–147 (1979).
  Medline CASGoogle Scholar
• 16  Tojo K. Random brick model for drug transport across stratum corneum. J. Pharm. Sci.76(12),889–891 (1987).
  Medline CASGoogle Scholar
• 17  Goffin V, Henry F, Pierard-Franchimont C, Pierard GE. Penetration enhancers assessed by corneoxenometry. Skin Pharmacol. Appl. Skin Physiol.13(5),280–284 (2000).
  Medline CASGoogle Scholar
• 18  Barry BW. Lipid–protein-partitioning theory of skin penetration enhancement. J. Control. Release15(3),237–248 (1991).
  CASGoogle Scholar
• 19  Karande P, Jain A, Ergun K, Kispersky V, Mitragotri S. Design principles of chemical penetration enhancers for transdermal drug delivery. Proc. Natl Acad. Sci. USA102(13),4688–4693 (2005).
  Medline CASGoogle Scholar
• 20  Kogan A, Garti N. Microemulsions as transdermal drug delivery vehicles. Adv. Colloid Interface Sci.123–126, 369–385 (2006).
  Google Scholar
• 21  Karande P, Jain A, Mitragotri S. Discovery of transdermal penetration enhancers by high-throughput screening. Nat. Biotechnol.22(2),192–197 (2004).▪▪ Identification of synergistic chemical permeation enhancer combinations through high-throughput screening.
  Medline CASGoogle Scholar
• 22  Karande P, Jain A, Mitragotri S. Insights into synergistic interactions in binary mixtures of chemical permeation enhancers for transdermal drug delivery. J. Control. Release115(1),85–93 (2006).
  Medline CASGoogle Scholar
• 23  Hamilton JG. Needle phobia: a neglected diagnosis. J. Fam. Practice41(2),169–175 (1995).
  Medline CASGoogle Scholar
• 24  Burkoth TL, Bellhouse BJ, Hewson G, Longridge DJ, Muddle AG, Sarphie DF. Transdermal and transmucosal powdered drug delivery. Crit. Rev. Ther. Drug Carrier Syst.16(4),331–384 (1999).
  Medline CASGoogle Scholar
• 25  Schramm J, Mitragotri S. Transdermal drug delivery by jet injectors: energetics of jet formation and penetration. Pharm. Res.19(11),1673–1679 (2002).
  Medline CASGoogle Scholar
• 26  Bremseth DL, Pass F. Delivery of insulin by jet injection: recent observations. Diabetes Technol. Ther.3(2),225–232 (2001).
  Medline CASGoogle Scholar
• 27  Denne JR, Andrews KL, Lees DV, Mook W. A survey of patient preference for insulin jet injectors versus needle and syringe. Diabetes Educ.18(3),223–227 (1992).
  Medline CASGoogle Scholar
• 28  Dean Hansi J, Fuller D, Osorio Jorge E. Powder and particle-mediated approaches for delivery of DNA and protein vaccines into the epidermis. Comp. Immunol. Microbiol. Infect. Dis.26(5–6),373–388 (2003).
  Medline CASGoogle Scholar
• 29  Spencer JM. Microdermabrasion. Am. J. Clin. Dermatol.6(2),89–92 (2005).
  MedlineGoogle Scholar
• 30  Fang JY, Lee WR, Shen SC, Fang YP, Hu CH. Enhancement of topical 5-aminolaevulinic acid delivery by erbium:YAG laser and microdermabrasion: a comparison with iontophoresis and electroporation. Br. J. Dermatol.151(1),132–140 (2004).
  MedlineGoogle Scholar
• 31  Fujimoto T, Shirakami K, Tojo K. Effect of microdermabrasion on barrier capacity of stratum corneum. Chem. Pharm. Bull.53(8),1014–1016 (2005).
  Medline CASGoogle Scholar
• 32  Gill HS, Andrews SN, Sakthivel SK et al. Selective removal of stratum corneum by microdermabrasion to increase skin permeability. Eur. J. Pharm. Sci.38(2),95–103 (2009).
  Medline CASGoogle Scholar
• 33  Park JH, Lee JW, Kim YC, Prausnitz MR. The effect of heat on skin permeability. Int. J. Pharm.359(1–2),94–103 (2008).▪▪ A study of the structural disruption of skin subjected to high temperature.
  Medline CASGoogle Scholar
• 34  Lee WR, Shen SC, Lai HH, Hu CH, Fang JY. Transdermal drug delivery enhanced and controlled by erbium:YAG laser: a comparative study of lipophilic and hydrophilic drugs. J. Control. Release75(1–2),155–166 (2001).
  Medline CASGoogle Scholar
• 35  Nelson JS, McCullough JL, Glenn TC, Wright WH, Liaw LH, Jacques SL. Mid-infrared laser ablation of stratum corneum enhances in vitro percutaneous transport of drugs. J. Invest. Dermatol.97(5),874–879 (1991).
  Medline CASGoogle Scholar
• 36  Gomez C, Costela A, Garcia-Moreno I, Llanes F, Teijon JM, Blanco D. Laser treatments on skin enhancing and controlling transdermal delivery of 5-fluorouracil. Laser Surg. Med.40(1),6–12 (2008).
  MedlineGoogle Scholar
• 37  Arora A, Prausnitz MR, Mitragotri S. Micro-scale devices for transdermal drug delivery. Int. J. Pharm.364(2),227–236 (2008).
  Medline CASGoogle Scholar
• 38  Henry S, McAllister DV, Allen MG, Prausnitz MR. Microfabricated microneedles: a novel approach to transdermal drug delivery. J. Pharm. Sci.87(8),922–925 (1998).
  Medline CASGoogle Scholar
• 39  Sullivan SP, Murthy N, Prausnitz MR. Minimally invasive protein delivery with rapidly dissolving polymer microneedles. Adv. Mater.20(5),933–938 (2008).
  Medline CASGoogle Scholar
• 40  Banks SL, Pinninti RR, Gill HS, Crooks PA, Prausnitz MR, Stinchcomb AL. Flux across microneedle-treated skin is increased by increasing charge of naltrexone and naltrexol in vitro. Pharm. Res.25(7),1677–1685 (2008).
  Medline CASGoogle Scholar
• 41  Gill HS, Prausnitz MR. Coated microneedles for transdermal delivery. J. Control. Release117(2),227–237 (2007).
  Medline CASGoogle Scholar
• 42  Lanke SSS, Kolli CS, Strom JG, Banga AK. Enhanced transdermal delivery of low molecular weight heparin by barrier perturbation. Int. J. Pharm.365(1–2),26–33 (2009).
  Medline CASGoogle Scholar
• 43  Wermeling DP, Banks SL, Hudson DA et al. Microneedles permit transdermal delivery of a skin-impermeant medication to humans. Proc. Natl Acad. Sci. USA105(6),2058–2063 (2008).
  Medline CASGoogle Scholar
• 44  Riviere JE, Heit MC. Electrically-assisted transdermal drug delivery. Pharm. Res.14(6),687–697 (1997).
  Medline CASGoogle Scholar
• 45  Warwick WJ, Huang NN, Waring WW et al. Evaluation of a cystic fibrosis screening system incorporating a miniature sweat stimulator and disposable chloride sensor. Clin. Chem.32(5),850–853 (1986).
  Medline CASGoogle Scholar
• 46  Squire SJ, Kirchhoff KT, Hissong K. Comparing two methods of topical anesthesia used before intravenous cannulation in pediatric patients. J. Pediatr. Healthcare14(2),68–72 (2000).
  Medline CASGoogle Scholar
• 47  Patel SR, Zhong H, Sharma A, Kalia YN. Controlled non-invasive transdermal iontophoretic delivery of zolmitriptan hydrochloride in vitro and in vivo. Eur. J. Pharm. Biopharm.72(2),304–309 (2009).
  Medline CASGoogle Scholar
• 48  Nakamura K, Katagai K, Mori K, Higo N, Sato S, Yamamoto K. Transdermal administration of salmon calcitonin by pulse depolarization-iontophoresis in rats. Int. J. Pharm.218(1–2),93–102 (2001).
  Medline CASGoogle Scholar
• 49  Pillai O, Panchagnula R. Transdermal delivery of insulin from poloxamer gel: ex vivo and in vivo skin permeation studies in rat using iontophoresis and chemical enhancers. J. Control. Release89(1),127–140 (2003).
  Medline CASGoogle Scholar
• 50  Rastogi SK, Singh J. Transepidermal transport enhancement of insulin by lipid extraction and iontophoresis. Pharm. Res.19(4),427–433 (2002).
  Medline CASGoogle Scholar
• 51  Suzuki Y, Nagase Y, Iga K et al. Prevention of bone loss in ovariectomized rats by pulsatile transdermal iontophoretic administration of human PTH_1–34. J. Pharm. Sci.91(2),350–361 (2002).
  Medline CASGoogle Scholar
• 52  Nair V, Panchagnula R. Physicochemical considerations in the iontophoretic delivery of a small peptide: in vitro studies using arginine vasopressin as a model peptide. Pharmacol. Res.48(2),175–182 (2003).
  Medline CASGoogle Scholar
• 53  Galinkin JL, Rose JB, Harris K, Watcha MF. Lidocaine iontophoresis versus eutectic mixture of local anesthetics (EMLA^®) for IV placement in children. Anesth. Analg.94(6),1484–1488 (2002).
  Medline CASGoogle Scholar
• 54  Runeson L, Haker E. Iontophoresis with cortisone in the treatment of lateral epicondylalgia (tennis elbow) – a double-blind study. Scand. J. Med. Sci. Sports12(3),136–142 (2002).
  Medline CASGoogle Scholar
• 55  Gupta SK, Bernstein KJ, Noorduin H, Van Peer A, Sathyan G, Haak R. Fentanyl delivery from an electrotransport system: delivery is a function of total current, not duration of current. J. Clin. Pharmacol.38(10),951–958 (1998).
  Medline CASGoogle Scholar
• 56  Singh J, Gross M, Sage B, Davis HT, Maibach HI. Regional variations in skin barrier function and cutaneous irritation due to iontophoresis in human subjects. Food Chem. Toxicol.39(11),1079–1086 (2001).
  Medline CASGoogle Scholar
• 57  Prausnitz MR. A practical assessment of transdermal drug delivery by skin electroporation. Adv. Drug Deliv. Rev.35(1),61–76 (1999).
  Medline CASGoogle Scholar
• 58  Denet AR, Preat V. Transdermal delivery of timolol by electroporation through human skin. J. Control. Release88(2),253–262 (2003).
  Medline CASGoogle Scholar
• 59  Zewert TE, Pliquett UF, Vanbever R, Langer R, Weaver JC. Creation of transdermal pathways for macromolecule transport by skin electroporation and a low toxicity, pathway-enlarging molecule. Bioelectrochem. Bioenerg.49(1),11–20 (1999).
  Medline CASGoogle Scholar
• 60  Mitragotri S. Effect of therapeutic ultrasound on partition and diffusion coefficients in human stratum corneum. J. Control. Release71(1),23–29 (2001).
  Medline CASGoogle Scholar
• 61  Tang H, Wang CCJ, Blankschtein D, Langer R. An investigation of the role of cavitation in low-frequency ultrasound-mediated transdermal drug transport. Pharm. Res.19(8),1160–1169 (2002).
  Medline CASGoogle Scholar
• 62  Mitragotri S, Blankschtein D, Langer R. Transdermal drug delivery using low-frequency sonophoresis. Pharm. Res.13(3),411–420 (1996).
  Medline CASGoogle Scholar
• 63  Mitragotri S, Blankschtein D, Langer R. Ultrasound-mediated transdermal protein delivery. Science269(5225),850–853 (1995).
  Medline CASGoogle Scholar
• 64  Mitragotri S, Edwards DA, Blankschtein D, Langer R. Mechanistic study of ultrasonically-enhanced transdermal drug-delivery. J. Pharm. Sci.84(6),697–706 (1995).
  Medline CASGoogle Scholar
• 65  Mitragotri S, Farrell J, Tang H, Terahara T, Kost J, Langer R. Determination of threshold energy dose for ultrasound-induced transdermal drug transport. J. Control. Release63(1–2),41–52 (2000).
  Medline CASGoogle Scholar
• 66  Cross SE, Roberts MS. Physical enhancement of transdermal drug application: is delivery technology keeping up with pharmaceutical development? Curr. Drug Delivery1(1),81–92 (2004).▪ Extensive review of the physical enhancement methods used in percutaneous drug delivery.
  Medline CASGoogle Scholar
• 67  Kost J, Pliquett U, Mitragotri S, Yamamoto A, Langer R, Weaver J. Synergistic effect of electric field and ultrasound on transdermal transport. Pharm. Res.13(4),633–638 (1996).
  Medline CASGoogle Scholar
• 68  Riviere JE, Monteiroriviere NA, Rogers RA, Bommannan D, Tamada JA, Potts RO. Pulsatile transdermal delivery of LHRH using electroporation: drug delivery and skin toxicology. J. Control. Release36(3),229–233 (1995).
  CASGoogle Scholar
• 69  Chang SL, Hofmann GA, Zhang L, Deftos LJ, Banga AK. The effect of electroporation on iontophoretic transdermal delivery of calcium regulating hormones. J. Control. Release66(2–3),127–133 (2000).
  Medline CASGoogle Scholar
• 70  Prausnitz MR. Microneedles for transdermal drug delivery. Adv. Drug Deliv. Rev.56(5),581–587 (2004).
  Medline CASGoogle Scholar
• 71  Chen H, Zhu H, Zheng J et al. Iontophoresis-driven penetration of nanovesicles through microneedle-induced skin microchannels for enhancing transdermal delivery of insulin. J. Control. Release139(1),63–72 (2009).
  Medline CASGoogle Scholar
• 72  Kasting GB, Smith RL, Anderson BD. In: Prodrugs: Topical and Ocular Drug Delivery. Sloan KB (Ed.). Marcel Dekker, NY, USA 117–161 (1992).▪ Discussion of prodrug design for transdermal delivery.
  Google Scholar
• 73  Qandil A, Al-Nabulsi S, Al-Taani B, Tashtoush B. Synthesis of piperazinylalkyl ester prodrugs of ketorolac and their in vitro evaluation for transdermal delivery. Drug Dev. Ind. Pharm.34(10),1054–1063 (2008).
  Medline CASGoogle Scholar
• 74  Kushnir M, Yaar A, Reichman A, Heldman E. Transdermal delivery of a levodopa prodrug; a pilot clinical trial. Mov. Disord.23,592 (2008).
  MedlineGoogle Scholar
• 75  Thomas JD, Majumdar S, Sloan KB. Soft alkyl ether prodrugs of a model phenolic drug: the effect of incorporation of ethyleneoxy groups on transdermal delivery. Molecules14(10),4231–4245 (2009).
  Medline CASGoogle Scholar
• 76  Strasinger CL, Scheff NN, Stinchcomb AL. Prodrugs and codrugs as strategies for improving percutaneous absorption. Expert Rev. Dermatol.3(2),221–233 (2008).
  CASGoogle Scholar
• 77  Vaddi HK, Banks SL, Chen J, Hammell DC, Crooks PA, Stinchcomb AL. Human skin permeation of 3-O-alkyl carbamate prodrugs of naltrexone. J. Pharm. Sci.98(8),2611–2625 (2009).
  Medline CASGoogle Scholar
• 78  Kiptoo PK, Paudel KS, Hammell DC et al. Transdermal delivery of bupropion and its active metabolite, hydroxybupropion: a prodrug strategy as an alternative approach. J. Pharm. Sci.98(2),583–594 (2009).
  Medline CASGoogle Scholar
• 79  Murphy M, Carmichael AJ. Transdermal drug delivery systems and skin sensitivity reactions: incidence and management. Am. J. Clin. Dermatol.1(6),361–368 (2000).▪ Discusses characteristics, sources, management and prevention of skin irritation reactions caused by drug delivery systems.
  Medline CASGoogle Scholar
• 80  Berner B, Wilson DR, Guy RH, Mazzenga GC, Clarke FH, Maibach HI. The relationship of pka and acute skin irritation in man. Pharm. Res.5(10),660–663 (1988).
  Medline CASGoogle Scholar
• 81  Berner BWD, Steffens RJ, Mazzenga GC, Hinz R, Guy RH, Maibach HI. The relationship between pka and skin irritation for a series of basic penetrants in man. Fundam. Appl. Toxicol.15(4),760–766 (1990).
  Medline CASGoogle Scholar
• 82  Andersen PH, Nangia A, Bjerring P, Maibach HI. Chemical and pharmacologic skin irritation in man. Contact Derm.25(5),283–289 (1991).
  Medline CASGoogle Scholar
• 83  Mangia A, Andersen PH, Berner B, Maibach HI. High dissociation constants (pKa) of basic permeants are associated with in vivo skin irritation in man. Contact Derm.34(4),237–242 (1996).
  MedlineGoogle Scholar
• 84  Johnson W. Final report on the safety assessment of capsicum annuum extract, capsicum annuum fruit extract, capsicum annuum resin, capsicum annuum fruit powder, capsicum frutescens fruit, capsicum frutescens fruit extract, capsicum frutescens resin, and capsaicin. Int. J. Toxicol.26(Suppl. 1),3–106 (2007).
  Google Scholar
• 85  Branco N, Lee I, Hongbo Z, Maibach HI. Long-term repetitive sodium lauryl sulfate-induced irritation of the skin: an in vivo study. Contact Derm.53(5),278–284 (2005).
  Medline CASGoogle Scholar
• 86  Fluhr JW, Darlenski R, Angelova-Fischer I, Tsankov N, Basketter D. Skin irritation and sensitization: mechanisms and new approaches for risk assessment. Skin Pharmacol. Physiol.21(3),124–135 (2008).▪ Discusses skin irritation and sensitization in detail as well as current methods used to determine their presence and extent.
  Medline CASGoogle Scholar
• 87  Fang JY, Tsai MJ, Huang YB, Wu PC, Tsai YH. Percutaneous absorption and skin erythema: quantification of capsaicin and its synthetic derivatives from gels incorporated with benzalkonium chloride by using non-invasive bioengineering methods. Drug Dev. Res.40(1),56–67 (1997).
  CASGoogle Scholar
• 88  Schmid-Wendtner MH, Korting HC. The pH of the skin surface and its impact on the barrier function. Skin Pharmacol. Physiol.19(6),296–302 (2006).
  MedlineGoogle Scholar
• 89  Antoine JL, Contreras JL, Van Neste DJ. pH influence of surfactant-induced skin irritation. Derm. Beruf Umwelt37(3),96–100 (1989).
  Medline CASGoogle Scholar
• 90  Ananthapadmanabhan KP, Lips A, Vincent C et al. pH-induced alterations in stratum corneum properties. Int. J. Cosmetic Sci.25(3),103–112 (2003).
  Medline CASGoogle Scholar
• 91  Williams A. Pharmaceutical solvents as vehicles for topical dosage forms. In: Solvent Systems and Their Selection in Pharmaceutics and Biopharmaceutics (Volume 6). Augustijns P, Brewster ME (Eds). Springer, NY, USA 403–426 (2007).
  Google Scholar
• 92  Matsumura H, Oka K, Umekage K et al. Effect of occlusion on human skin. Contact Derm.33(4),231–235 (1995).
  Medline CASGoogle Scholar
• 93  Homick JLKR, Reschke MF, Degioanni J, Cintron-Trevino NM. Transdermal scopolamine in the prevention of motion sickness: evaluation of the time course of efficacy. Aviat. Space Environ. Med.54(11),994–1000 (1983).
  Medline CASGoogle Scholar
• 94  Hurkmans JF, Bodde HE, Driel LM, Doorne HV, Junginger HE. Skin irritation caused by transdermal drug delivery systems during long-term (5 days) application. Br. J. Dermatol.112(4),461–467 (1985).
  Medline CASGoogle Scholar
• 95  Van der Valk PG, Maibach HI. Post-application occlusion substantially increases the irritant response of the skin to repeated short-term sodium lauryl sulfate (SLS) exposure. Contact Derm.21(5),335–338 (1989).
  Medline CASGoogle Scholar
• 96  Tsen-Fang T, Maibach HI. How irritant is water? An overview. Contact Derm.41(6),311–314 (1999).
  MedlineGoogle Scholar
• 97  Dwyer CM, Forsyth A. Allergic contact dermatitis from methacrylates in a nicotine transdermal patch. Contact Derm.30(5),309–310 (1994).
  Medline CASGoogle Scholar
• 98  Ross D, Rees M, Godfree V et al. Randomised crossover comparison of skin irritation with two transdermal oestradiol patches. BMJ315(7103),288 (1997).
  Medline CASGoogle Scholar
• 99  Marier JF, Lor M, Potvin D, Dimarco M, Morelli G, Saedder EA. Pharmacokinetics, tolerability, and performance of a novel matrix transdermal delivery system of fentanyl relative to the commercially available reservoir formulation in healthy subjects. J. Clin. Pharmacol.46(6),642–653 (2006).
  Medline CASGoogle Scholar
• 100  Wester RC, Patel R, Nacht S, Leyden J, Melendres J, Maibach H. Controlled release of benzoyl peroxide from a porous microsphere polymeric system can reduce topical irritancy. J. Am. Acad. Dermatol.24(5 Pt 1),720–726 (1991).
  Medline CASGoogle Scholar
• 101  de Leeuw J, de Vijlder HC, Bjerring P, Neumann HAM. Liposomes in dermatology today. J. Eur. Acad. Dermatol.23(5),505–516 (2009).▪ Discusses the characteristics of liposome formulations, a synopsis of the state of liposome research and how liposomal formulations are impacting the field of dermal drug delivery.
  Medline CASGoogle Scholar
• 102  Schäfer-Korting M, Korting HC, Ponce-Pöschl E. Liposomal tretinoin for uncomplicated acne vulgaris. Clin. Invest.72(12),1086–1091 (1994).
  Medline CASGoogle Scholar
• 103  Zhai H, Willard P, Maibach HI. Evaluating skin-protective materials against contact irritants and allergens. Contact Derm.38(3),155–158 (1998).
  Medline CASGoogle Scholar
• 104  Wigger-Alberti W, Hinnen U, Elsner P. Predictive testing of metalworking fluids: a comparison of 2 cumulative human irritation models and correlation with epidemiological data. Contact Derm.6(1),14–20 (1997).
  Google Scholar
• 105  Ben-Shabat S, Baruch N, Sintov AC. Conjugates of unsaturated fatty acids with propylene glycol as potentially less-irritant skin penetration enhancers. Drug Dev. Ind. Pharm.33(11),1169–1175 (2007).
  Medline CASGoogle Scholar
• 106  Sintov A, Ben-Shabat S. Design of fatty acid conjugates for dermal delivery and topical therapeutics. Anglais23(1),67–87 (2006).
  CASGoogle Scholar
• 107  Karande P, Mitragotri S. Enhancement of transdermal drug delivery via synergistic action of chemicals. Biochim. Biophys. Acta Biomembranes1788(11),2362–2373 (2009).
  Medline CASGoogle Scholar
• 108  Wilson DE, Kaidbey K, Boike SC, Jorkasky DK. Use of topical corticosteroid pretreatment to reduce the incidence and severity of skin reactions associated with testosterone transdermal therapy. Clin. Ther.20(2),299–306 (1998).
  MedlineGoogle Scholar
• 109  Amkraut AA, Jordan WP, Taskovich L. Effect of coadministration of corticosteroids on the development of contact sensitization. J. Am. Acad. Dermatol.35(1),27–31 (1996).
  Medline CASGoogle Scholar
• 110  Andersen F, Hedegaard K, Petersen TK, Bindslev-Jensen C, Fullerton A, Andersen KE. Anti-irritants I: Dose-response in acute irritation. Contact Derm.55(3),148–154 (2006).
  Medline CASGoogle Scholar
• 111  Andersen F, Hedegaard K, Petersen TK, Bindslev-Jensen C, Fullerton A, Andersen KE. Comparison of the effect of glycerol and triamcinolone acetonide on cumulative skin irritation in a randomized trial. J. Am. Acad. Dermatol.56(2),228–235 (2007).
  MedlineGoogle Scholar
• 112  Huang YB, Tsai YH, Chang JS, Liu JC, Tsai MJ, Wu PC. Effect of antioxidants and anti-irritants on the stability, skin irritation and penetration capacity of captopril gel. Int. J. Pharm.241(2),345–351 (2002).
  Medline CASGoogle Scholar
• 201  Micromedex^® 1.0 (Healthcare Series) Thomson Reuters www.thomsonhc.com/home (Accessed 27 February 2010)
  Google Scholar
• 202  Rx List www.rxlist.com/script/main/hp.asp (Accessed 27 February 2010)
  Google Scholar
• 203  Zars Pharma www.zars.com (Accessed 1 March 2010)
  Google Scholar
• 204  Purdue Pharma L.P. www.purduepharma.com (Accessed 28 February 2010)
  Google Scholar
• 205  NuPathe^® Inc. www.nupathe.com (Accessed 28 February 2010)
  Google Scholar
• 206  ClinicalTrials.gov www.clinicaltrials.gov (Accessed 28 February 2010)
  Google Scholar
• 207  DURECT www.durect.com (Accessed 28 February 2010)
  Google Scholar
• 208  TransPharma Medical™ www.transpharma-medical.com (Accessed 28 February 2010)
  Google Scholar
• 209  Drugs@FDA www.accessdata.fda.gov/Scripts/cder/DrugsatFDA (Accessed 27 February 2010)
  Google Scholar
• 210  European Medicines Agency. European Medicines Agency recommends the suspension of the marketing authorisation of IONSYS (fentanyl hydrochloride) (2008) www.ema.europa.eu/humandocs/PDFs/EPAR/ionsys/61385208en.pdf (Accessed 28 February 2010)
  Google Scholar
• 211  Drugs.com www.Drugs.com (Accessed 27 February 2010)
  Google Scholar
• 212  DailyMed www.Dailymed.nlm.nih.gov (Accessed 27 February 2010)
  Google Scholar